Physician profile
Mark E Frazer
NPI 1194824672
$2,624.24
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,847 · 2020: $777.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $421.12 | 2019-2020 | |
| Amgen INC. | $283.39 | 2019-2020 | |
| Amarin Pharma, INC. | $226.02 | 2019-2020 | |
| Pfizer INC. | $221.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $185.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $159.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.41 | 2019-2020 | |
| Novo Nordisk INC | $148.13 | 2019-2020 | |
| Lilly USA, LLC | $139.83 | 2019 | |
| Glaxosmithkline, LLC. | $112.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $103.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $100.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.51 | 2019-2020 | |
| Astellas Pharma US INC | $75.62 | 2019-2020 | |
| Grifols USA, LLC | $74.61 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $23.53 | 2019-2020 | |
| Genentech USA, INC. | $21.63 | 2019 | |
| Daiichi Sankyo INC. | $15.63 | 2019 | |
| Abbott Laboratories | $15.07 | 2020 | |
| Circassia INC. | $13.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Frazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.